Clinical Trials Browser

Completed × Interleukin-2 × Dermatologic × Clear all

NCT06151847 2026-04-30

Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma

Phase 2 Completed

Melanoma

NCT05628883 2026-04-02

Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma

Phase 1 Completed

Uveal Melanoma, Melanoma

NCT01659151 2026-02-20

Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma

Phase 2 Completed

17 enrolled 11 charts

Melanoma, Neoplasm Metastasis

NCT01005745 2025-12-19

Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma

Phase NA Completed

19 enrolled 7 charts

Melanoma

NCT01319565 2025-12-19

Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI...

Phase 2 Completed

102 enrolled 12 charts

Melanoma, Skin Neoplasms

NCT01701674 2025-12-19

Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts

Phase NA Completed

13 enrolled 10 charts

Melanoma, Skin Neoplasms

NCT04812470 2025-09-22

HAITILS

Phase 1 Completed

Uveal Melanoma, Melanoma

NCT02652455 2025-08-19

Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma

Phase EARLY_PHASE1 Completed

Melanoma, Skin Neoplasms

NCT02278887 2025-03-10

TIL

Phase 3 Completed

Melanoma

NCT03475134 2025-02-11

TIL-ACT After NMA Chemo with IL-2 and Nivo Rescue in Metastatic Melanoma (mMEL)

Phase 1 Completed

Melanoma

NCT04165967 2024-04-10

BaseTIL

Phase 1 Completed

Melanoma

NCT00019448 2024-03-04

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

Phase 2 Completed

Melanoma, Neoplasms, Skin Neoplasms

NCT00020267 2024-03-04

Vaccine Therapy in Treating Patients With Metastatic Cancer

Phase 1 Completed

BreastDermatologicGastrointestinalSarcomaThoracic

Uveal Melanoma, Bone Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Eye Neoplasms, Gastrointestinal Neoplasms, Lung Neoplasms, Melanoma, Neoplasms, Rectal Neoplasms, Recurrence, Sarcoma, Osteosarcoma, Skin Neoplasms, Colorectal Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral, Breast Neoplasms, Male, Muscle Neoplasms, Genetic Diseases, Inborn, Histiocytoma, Malignant Fibrous

NCT00020475 2024-03-04

Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye

Phase 2 Completed

Uveal Melanoma, Eye Neoplasms, Neoplasms

NCT03850691 2024-01-17

Radiation and Combination Immunotherapy for Melanoma

Phase 2 Completed

4 enrolled 11 charts

Melanoma

NCT01288963 2023-06-15

IL-2 "SELECT" Tissue Collection Protocol in Patients With Advanced Melanoma

Melanoma

NCT03841110 2023-05-01

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Phase 1 Completed

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Melanoma, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT03158935 2020-08-14

ACTIVATE

Phase 1 Completed

Melanoma

NCT02354690 2020-03-23

Vemurafenib and TIL Therapy for Metastatic Melanoma

Phase 1/2 Completed

13 enrolled 12 charts

Melanoma

NCT01266603 2020-02-19

High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI

Phase 2 Completed

44 enrolled 11 charts

Melanoma

NCT02379195 2020-01-22

Peginterferon and TIL Therapy for Metastatic Melanoma

Phase 1/2 Completed

12 enrolled 10 charts

Melanoma

NCT01603212 2019-05-21

Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor

Phase 1 Completed

Melanoma

NCT00470015 2019-02-19

Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV Melanoma

Phase 1 Completed

Melanoma

NCT01124734 2019-02-12

High Dose Interleukin-2 Followed by Intermittent Low Dose Temozolomide in Patients With Melanoma

Phase 2 Completed

17 enrolled 11 charts

Melanoma

NCT00726739 2017-12-28

Aldesleukin With or Without Vaccine Therapy in Treating Patients With Stage IV Melanoma

Phase 2 Completed

21 enrolled 12 charts

Melanoma

NCT00019682 2017-11-20

Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma

Phase 3 Completed

185 enrolled 11 charts

Melanoma

NCT00062036 2017-07-02

Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma

Phase 1/2 Completed

Melanoma

NCT00200577 2017-06-01

TIL

Phase 3 Completed

Melanoma

NCT00871481 2017-04-19

Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma

Phase 1/2 Completed

Melanoma

NCT00553306 2017-02-15

Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma

Phase 1/2 Completed

Melanoma

NCT01278940 2016-08-15

Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Advanced Malignant Melanoma

Phase 1/2 Completed

Melanoma

NCT00096382 2015-10-28

Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma

Phase 2 Completed

34 enrolled 11 charts

Melanoma

NCT00923195 2015-10-28

Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma

Phase 2 Completed

4 enrolled 11 charts

Melanoma, Skin Neoplasms

NCT00937625 2015-08-18

T-cell Based Immunotherapy for of Melanoma

Phase 1/2 Completed

Melanoma

NCT01480323 2015-07-21

A Phase II Study to Evaluate Safety and Efficacy of Combined Treatment With Ipilimumab and Intratumoral Interleukin-2

Phase 2 Completed

Melanoma

NCT01672450 2015-07-08

A Study of Intratumoral Injection of Interleukin-2 and Ipilimumab in Patients With Unresectable Stages III-IV Melanoma

Phase 1 Completed

Melanoma

NCT00276835 2015-04-10

Genistein and Interleukin-2 in Treating Patients With Metastatic Melanoma or Kidney Cancer

Phase EARLY_PHASE1 Completed

DermatologicGenitourinary

Carcinoma, Renal Cell, Kidney Neoplasms, Melanoma

NCT00006237 2015-03-25

S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma

Phase 3 Completed

432 enrolled 7 charts

Melanoma

NCT00003222 2014-12-19

Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma

Phase 2 Completed

40 enrolled 10 charts

Melanoma

NCT01339663 2014-04-21

Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Metastatic Melanoma

Phase 1 Completed

Melanoma

NCT00203879 2013-09-05

Study of MAGE-3/Melan-A/gp 100/NA17 and rhIL-12 With/Out Low Dose IL-2 in Metastatic Melanoma

Phase 2 Completed

Melanoma

NCT01743157 2013-08-29

BBI

Phase 1/2 Completed

Melanoma

NCT00513604 2013-06-03

Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma

Phase 2 Completed

158 enrolled 14 charts

Melanoma, Melanoma, Experimental, Neoplasms, Skin Neoplasms

NCT00085423 2013-04-10

Cyclophosphamide, Fludarabine, and High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma

Phase 2 Completed

20 enrolled 9 charts

Melanoma

NCT00005949 2013-01-16

Vaccine Plus Interleukin-2 in Treating Patients With Advanced Melanoma

Phase 2 Completed

Melanoma

NCT00970996 2013-01-03

BCAA

Phase 1 Completed

Melanoma

NCT00509288 2012-12-28

Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered Lymphocytes

Phase 2 Completed

24 enrolled 11 charts

Melanoma, Skin Neoplasms

NCT00001832 2012-12-21

Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma

Phase 2 Completed

170 enrolled 23 charts

BreastDermatologic

Breast Neoplasms, Melanoma, Neoplasm Metastasis

NCT00328861 2012-11-05

Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer

Phase 2 Completed

8 enrolled 8 charts

DermatologicGenitourinary

Kidney Neoplasms, Melanoma

NCT00059475 2012-10-23

Peptide Vaccination for Patients at High Risk for Recurrent Melanoma

Phase 2 Completed

138 enrolled 16 charts

Melanoma